CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans
CorMedix (CRMD) reported third-quarter 2026 consolidated revenue of $54.5 million, a decrease from $104.3 million in the prior year period. This decline was primarily driven by lower net pricing for DefenCath as it transitioned to a post-TDAPA reimbursement period. Despite this, outpatient dialysis customer utilization remained steady, and the company benefited from a $5 million favorable adjustment regarding Medicaid rebates and product return allowances. The company is pivoting toward diversification through the planned acquisition of Heron Therapeutics assets, which are expected to contribute between $125 million and $150 million in pro forma revenue for 2027. Management anticipates achieving $45 million to $60 million in annualized operating cost synergies by the end of 2027. With $355.2 million in cash and cash equivalents, CorMedix maintains significant liquidity to fund this acquisition and its ongoing operations.
Tickers: $CRMD
Topics: Asset acquisition DefenCath pricing transition Financial guidance Heron Therapeutics Revenue decrease
Read the full article at Motley Fool
Part of the story CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans (9 articles)